APA (7th ed.) Citation

E, A., K, B., M, S., S, P., F, S., P, P., . . . L, K. (2025). The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer. Molecular cancer, 24(1), 134. https://doi.org/10.1186/s12943-025-02320-y

Chicago Style (17th ed.) Citation

E, Atas, et al. "The Anti-diabetic PPARγ Agonist Pioglitazone Inhibits Cell Proliferation and Induces Metabolic Reprogramming in Prostate Cancer." Molecular Cancer 24, no. 1 (2025): 134. https://doi.org/10.1186/s12943-025-02320-y.

MLA (9th ed.) Citation

E, Atas, et al. "The Anti-diabetic PPARγ Agonist Pioglitazone Inhibits Cell Proliferation and Induces Metabolic Reprogramming in Prostate Cancer." Molecular Cancer, vol. 24, no. 1, 2025, p. 134, https://doi.org/10.1186/s12943-025-02320-y.